Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment (left eye)
ICD-10 E09.3542 is a billable code used to indicate a diagnosis of drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment (left eye).
E09.3542 refers to diabetes mellitus that has been induced by drugs or chemicals, leading to significant complications such as proliferative diabetic retinopathy. This condition is characterized by the growth of abnormal blood vessels in the retina, which can result in vision loss. In this specific case, the patient presents with both traction retinal detachment and rhegmatogenous retinal detachment in the left eye, indicating a severe progression of the retinopathy. The management of this condition requires careful monitoring of blood glucose levels, typically assessed through HbA1c levels, which should ideally be maintained below 7% to minimize complications. Insulin management may be necessary, especially if the diabetes is severe or poorly controlled. The presence of combined retinal detachments complicates the clinical picture, necessitating potential surgical interventions and close collaboration between endocrinologists and ophthalmologists.
Detailed history of diabetes management, including medication history and HbA1c levels.
Patients with drug-induced diabetes requiring insulin therapy and monitoring.
Ensure documentation reflects the cause of diabetes and any related complications.
Comprehensive eye examination reports, including findings related to retinopathy and retinal detachment.
Patients presenting with vision changes due to diabetic retinopathy.
Document the type of retinal detachment and any surgical interventions performed.
Used for treatment of proliferative diabetic retinopathy.
Document the extent of retinopathy and treatment rationale.
Ophthalmology must provide detailed reports on the procedure and patient response.
The drug or chemical etiology is crucial as it determines the management and treatment approach for the diabetes and its complications.
HbA1c levels should be monitored at least every three months, or more frequently if the patient is not meeting glycemic targets.
